

# Contents

<i>Preface</i>		vii
<i>List of Contributors</i>		xix
<b>Part 1</b>	<b>General Management of Renal Patients</b>	<b>1</b>
Chapter 1	Assessment of Patients with Renal Diseases <i>Sydney C. W. Tang</i>	3
	1.1 Urinalysis	3
	1.2 Interpretation of Laboratory Tests	6
	1.3 Renal Biopsy	11
Chapter 2	Acid-Base Disturbances <i>Orly F. Kohn and Todd S. Ing</i>	15
	2.1 Simple Acid-Base Disturbances	15
	2.2 Mixed Acid-Base Disturbances	18
	2.3 Metabolic Acidosis	19
	2.4 Metabolic Alkalosis	31
	2.5 Combined Metabolic Acidosis and Metabolic Alkalosis	35
	2.6 Respiratory Acid-Base Disturbances in Renal Patients	36
Chapter 3	Potassium Disturbances <i>James C. M. Chan</i>	39
	3.1 Introduction	39
	3.2 Hyperkalemia	39
	3.3 Hypokalemia	42
	3.4 Potassium Homeostasis	43

Chapter 4	Sodium and Water Disturbances	45
	<i>Ramin Sam and Todd S. Ing</i>	
4.1	Urinary Dilution and Concentration	45
4.2	Diseases of Urinary Concentration and Dilution	52
4.3	Hyponatremia	54
4.4	Complications of Hyponatremia	65
4.5	Risk Factors for Hyponatremic Encephalopathy	65
4.6	Treatment of Hyponatremias (Other than Translocational Hyponatremia)	66
4.7	Hypernatremia	70
Chapter 5	Hypercalcemia, Hypocalcemia, and Hypomagnesemia	81
	<i>Peter G. Kerr</i>	
5.1	Introduction	81
5.2	Hypercalcemia	82
5.3	Hypocalcemia	84
5.4	Hypomagnesemia	86
Chapter 6	Acute Renal Failure	89
	<i>Kar Neng Lai</i>	
6.1	Definition	89
6.2	Incidence and Prevalence	91
6.3	Classification and Causes	91
6.4	Diagnosis	93
6.5	Management	100
6.6	Prevention and What to Avoid	105
6.7	Recovery from Acute Tubular Necrosis	106
6.8	Prognosis	106
6.9	Future Novel Treatments	107
Chapter 7	Selected Glomerular Disorders	109
	<i>Kar Neng Lai</i>	
7.1	Minimal Change Nephropathy (MCN)	109
7.2	Idiopathic Membranous Nephropathy	111
7.3	Focal Segmental Glomerulosclerosis (FSGS)	114

	7.4	IgA Nephropathy (IgAN)	115
	7.5	Lupus Nephritis (LN)	120
	7.6	Diabetic Nephropathy (DN)	122
	7.7	Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Systemic Vasculitis (AASV)	124
Chapter 8		Hypertension and Renal Disease in Pregnancy <i>Susan Hou</i>	127
	8.1	Hypertension in Pregnancy	127
	8.2	Renal Disease in Pregnancy	132
Chapter 9		Selected Problems in General Nephrology <i>Kar Neng Lai</i>	137
	9.1	Hepatorenal Syndrome (HRS)	137
	9.2	Contrast-Induced Nephropathy (CIN)	142
	9.3	Rhabdomyolysis	144
	9.4	ARF in Hematopoietic Cell Transplant (HCT)	146
Chapter 10		Urinary Tract Infections <i>Evan J. C. Lee</i>	149
	10.1	Asymptomatic Bacteriuria	149
	10.2	Acute Cystitis	149
	10.3	Recurrent Cystitis	150
	10.4	Acute Pyelonephritis	152
	10.5	Infection Associated with Obstruction or Stones	152
	10.6	Infection Associated with Urinary Catheters	154
Part II		Chronic Renal Failure and Dialysis	155
Chapter 11		Principle of Management for Patients with Chronic Kidney Disease <i>Meguid El Nahas and Mohsen El Kossi</i>	157
	11.1	Background	157
	11.2	Detection of CKD	158
	11.3	Referral of Patients to Nephrology Centers	160

	11.4 Interventions Aimed at Slowing the Progression of CKD	161
	11.5 Slowing the Progression of CKD	163
	11.6 Interventions Aimed at Reducing CKD Complications	164
	11.7 Preparation of Patients for Renal Replacement Therapy (RRT)	166
	11.8 Conclusion	166
Chapter 12	Acceptance into the Chronic Dialysis Program <i>Dae-Suk Han</i>	169
	12.1 Criteria for Acceptance into the Chronic Dialysis Program	169
	12.2 Clinical Indications for Commencing Dialysis	173
Chapter 13	Peritoneal Dialysis — Management of Tenckhoff Catheter and Ultrafiltration Problems <i>Wai-Kei Lo</i>	175
	13.1 Introduction	175
	13.2 Peritoneal Dialysis Catheter — Tenckhoff Catheter	175
	13.3 Tenckhoff Catheter Exit-Site Infection	178
	13.4 Ultrafiltration Problems	179
	13.5 Peritoneal Equilibration Test (PET)	184
Chapter 14	Management of CAPD-Related Peritonitis <i>Philip K. T. Li and Kai-Ming Chow</i>	191
	14.1 Diagnosis	191
	14.2 Peritonitis Rate	191
	14.3 Organisms for Peritonitis	192
	14.4 Management	193
	14.5 Complications	196
	14.6 Prevention	197
Chapter 15	Hemodialysis <i>Bharathi Reddy and Alfred K. H. Cheung</i>	201
	15.1 Mechanisms of Solute Transport	201
	15.2 Hemodialysis Membranes	202

15.3	Dialysate	205
15.4	Hemodialysis Apparatus	208
15.5	Vascular Access	212
15.6	Anticoagulation	220
15.7	Chronic Hemodialysis Prescription	223
Chapter 16	Hemofiltration and Hemodiafiltration <i>Matthew K. L. Tong</i>	227
16.1	Introduction	227
16.2	Hemofiltration versus Hemodialysis	227
16.3	Technical Requirements for Hemofiltration and Hemodiafiltration	228
16.4	Evolution for Hemodiafiltration	228
16.5	Evidence for Clinical Efficacy in Hemofiltration and Hemodiafiltration	229
16.6	Potential Complications and Drawbacks	230
16.7	Indications for Hemofiltration/ Hemodiafiltration	230
16.8	Prescription	231
Chapter 17	Adequacy of Dialysis and Dietary Advice <i>Simon J. Davies and Barbara Engel</i>	235
17.1	Adequacy of Dialysis	235
17.2	Measuring Small-Solute Clearance	236
17.3	Present Strategy for Achieving Adequate Dialysis	237
17.4	Protein Catabolic Rate (PCR) or Normalized Protein Nitrogen Appearance (nPNA) Rate	240
17.5	Dietary Advice	241
Chapter 18	Prevention and Management of Renal Osteodystrophy <i>David B. N. Lee</i>	251
18.1	Introduction	251
18.2	Renal Osteodystrophy: Classification	251
18.3	Renal Osteodystrophy: Diagnostic Tests	259
18.4	Treatment of Hyperparathyroidism	259
18.5	Parathyroidectomy	263

	18.6 Treatment of Hypercalcemia in Dialysis Patients	270
	18.7 Other Components of Renal Osteodystrophy	272
	18.8 Use of Low-Calcium Dialysate	278
Chapter 19	Treatment of Renal Anemia <i>Bruce A. Pussell and Rowan G. Walker</i>	283
	19.1 Causes of Anemia in CKD	283
	19.2 ESA Prescription	283
	19.3 Target Levels for Hemoglobin	285
	19.4 Failure to Respond to ESAs	287
	19.5 Hemoglobin Variability	289
Chapter 20	Bleeding Tendency and Hepatitis B Vaccination <i>Bo-Ying Choy and Kar Neng Lai</i>	293
	20.1 Management of Bleeding Tendency in Dialysis/Uremic Patients	293
	20.2 Hepatitis B Vaccination	296
Chapter 21	Routine Investigations for Dialysis Patients <i>Sydney C. W. Tang</i>	301
	21.1 Predialysis Workup	301
	21.2 Routine Investigations During Maintenance Dialysis	302
	21.3 Assessment of Suitability for Kidney Transplantation	302
<b>Part III</b>	<b>Renal Transplantation</b>	<b>307</b>
Chapter 22	Pretransplantation Donor and Recipient Workup <i>Laurence K. Chan and Siu-Kim Chan</i>	309
	22.1 Recipient Selection and Pretransplant Evaluation	309
	22.2 Live Donor Evaluation	324
	22.3 Deceased (Cadaver) Donor Evaluation	331

Chapter 23	Management Guidelines Peritransplantation <i>Jeremy R. Chapman</i>	341
	23.1 The Recipient Before Transplantation	341
	23.2 Investigations After Renal Transplantation	348
	23.3 Prophylactic Immunosuppression	351
	23.4 Highly Sensitized Recipients	358
	23.5 Other Prophylactic Measures	360
	23.6 Checklist When Discharging the Patient from the Ward	362
Chapter 24	Prophylaxis, Monitoring, and Preemptive Therapy for Potential Complications After Renal Transplantation <i>Sing-Leung Lui</i>	365
	24.1 Prophylaxis Against Peptic Ulceration	365
	24.2 Prophylaxis and Treatment of Tuberculosis	365
	24.3 Prophylaxis and Treatment of Candidiasis	367
	24.4 Prophylaxis and Treatment of Pneumocystis Pneumonia	368
	24.5 Monitoring and Preemptive Therapy for Cytomegalovirus Disease	369
Chapter 25	Medical Complications After Renal Transplantation <i>Daniel T. M. Chan</i>	373
	25.1 Acute Rejection	373
	25.2 Infective Complications	374
	25.3 Chronic Renal Allograft Dysfunction	379
	25.4 Gastrointestinal Complications	381
	25.5 Graft Renal Artery Stenosis	381
	25.6 Malignancies and Posttransplant Lymphoproliferative Disorder (PTLD)	381
	25.7 Metabolic Complications	382
	25.8 Cardiovascular Complications and Hypertension	383
	25.9 Erythrocytosis and Anemia	384
	25.10 Hyperparathyroidism, Renal Osteodystrophy, and Osteoporosis	384

<b>Part IV</b>	<b>Special Renal Investigations</b>	<b>387</b>
Chapter 26	Diagnosis of Renal Tubular Acidosis <i>James C. M. Chan</i>	389
	26.1 Introduction	389
	26.2 Classification of RTA	390
	26.3 Clinical Picture	390
	26.4 Laboratory Measurements in Diagnosing RTA	394
	26.5 Diagnostic Approach	397
Chapter 27	Treatment of Renal Tubular Acidosis <i>James C. M. Chan</i>	401
	27.1 Treatment of Type 1 and Type 2 Renal Tubular Acidosis (RTA)	401
	27.2 Treatment of Type 4 RTA	402
<b>Part V</b>	<b>Radiology in Renal Patients</b>	<b>405</b>
Chapter 28	Imaging and Interventional Treatment of Nephrological Problems <i>Andrew S. H. Lai and Ferdinand S. K. Chu</i>	407
	28.1 Deranged Renal Function	407
	28.2 Urinary Tract Infection (UTI)	408
	28.3 Stone Disease and Renal Colic	409
	28.4 Hematuria	410
	28.5 Hypertension	411
	28.6 Renal Osteodystrophy	415
	28.7 Hyperparathyroidism	417
	28.8 Complications of Contrast Imaging in Renal Patients	419
Chapter 29	Imaging and Interventional Treatment of Dialysis-Related Problems <i>Andrew S. H. Lai and Ferdinand S. K. Chu</i>	423
	29.1 Temporary and Tunneled Catheter Access	423
	29.2 Tunneled Catheter Failure	426
	29.3 Pre-arteriovenous Fistula Workup	427
	29.4 Poor Flow in Arteriovenous Fistula or Polytetrafluoroethylene (PTFE) Graft	428

	29.5 Complications Related to Continuous Ambulatory Peritoneal Dialysis (CAPD)	429
Chapter 30	Imaging and Interventional Treatment of Renal Transplant-Related Problems <i>Ferdinand S. K. Chu and Andrew S. H. Lai</i>	433
	30.1 Imaging of the Donor	433
	30.2 Imaging of the Recipient	434
	30.3 Graft Dysfunction and Other Graft Problems	434
	30.4 Surgical Complications of Graft Kidneys	435
	30.5 Arteriovenous Fistula (AVF) and Pseudoaneurysm	440
<b>Part VI</b>	<b>Drug Use in Renal Patients</b>	<b>443</b>
Chapter 31	Drug Doses in Patients with Renal Impairment <i>Siu-Kim Chan and Laurence K. Chan</i>	445
	31.1 Influence of Renal Impairment on Drug Absorption and Bioavailability	445
	31.2 Influence of Renal Impairment on Volume of Distribution and Protein Binding	446
	31.3 Influence of Renal Impairment on Drug Elimination	447
	31.4 Dosing of Drugs in the Presence of Renal Impairment	448
	31.5 Drug Removal During Hemodialysis and Peritoneal Dialysis	449
	31.6 Drug Removal During Continuous Renal Replacement Therapy (CRRT)	449
	31.7 Therapeutic Drug Monitoring	450
Chapter 32	Recommended Maintenance Drug Doses in Patients with Renal Impairment and in HD/CAPD/CVVH <i>Laurence K. Chan and Siu-Kim Chan</i>	451
	32.1 Antibiotics	452
	32.2 Antituberculosis Antibiotics	458
	32.3 Antifungal Agents	459

32.4	Antiviral Agents	460
32.5	Analgesics	462
32.6	Antihypertensive Drugs and Diuretics	463
32.7	Antiarrhythmic Agents	469
32.8	Oral Hypoglycemic Agents	470
32.9	Lipid-Lowering Agents	471
32.10	Gastrointestinal Agents	471
32.11	Neurological Agents/Anticonvulsants	473
32.12	Arthritis and Gout	474
32.13	NSAIDs	475
32.14	Sedatives	476
32.15	Antipsychotics	478
32.16	Antidepressants	479
32.17	Anticoagulants	479
32.18	Antihemophilic Agent	480
32.19	Chemotherapy	481
32.20	Iron-Chelating Agent	482
32.21	Immunosuppressants	483
Chapter 33	Drug Interactions with Commonly Used Immunosuppressants	485
	<i>Laurence K. Chan and Siu-Kim Chan</i>	
33.1	Cyclosporine	486
33.2	Tacrolimus	486
33.3	Mycophenolic Acid (MMF or Myfortic)	487
33.4	The TOR Inhibitors: Sirolimus and Everolimus	489
33.5	Potential Drug Interactions Among Commonly Used Immunosuppressants	490
Index		495